Abstract
Background: The Alzheimers Disease Assessment Scale – Cognitive Subscale (ADAS-Cog) has become the de facto gold standard for assessing the efficacy of anti-dementia treatments. However, manual administration of the ADAS-Cog is subject to procedural inconsistencies, including scoring and transcription errors, which can introduce unwanted variance and compromise data quality within and across sites and trials. To address such concerns, a computerized version was developed that integrates, rather than replaces, the examiner, standardizes administration, and uses electronic data capture at the point of patient contact. The examiner can control administration and pacing, pause or repeat digitized instructions, score verbal report and overt behavioral performance, and freely interact with the subject. Purpose: To conduct psychometric comparisons of traditional, paper-based administration of the standard ADAS-Cog (sADAS) with examiner- assisted administration of the computerized ADAS-Cog (cADAS). Methods: Eighty-eight patients (39M; 49F) with mild to moderate Alzheimers disease were tested on three occasions with each version over a period of one year with one month between paired visits. Results: Intraclass Correlation Coefficients (ICC) comparisons between sADAS and cADAS were significant for total score (ICC=0.96) and all subscores (ICCs ranged 0.78-0.93), with no significant differences on paired t-tests. The mean ICCs across cADAS scores for test-retest reliability for short-term (mean ICC=0.96) and long-term (mean ICC=0.91) comparisons were significantly higher than across sADAS scores (mean ICCs were 0.87 and 0.84, respectively). Conclusions: These results indicate that examiner-assisted, computerized administration is equivalent to traditional, paper-based administration, and shows significantly greater test-retest reliability.
Keywords: CMINDS, cognitive assessment, computerized ADAS-Cog, concurrent validity, clinical trials, psychometric comparison, test-retest reliability, Alzheimer's Disease Assessment Scale, ideational praxis, mild cognitive impairment, ADCS, NINCDS, ADRDA, MMSE
Current Alzheimer Research
Title: Psychometric Comparison of Standard and Computerized Administration of the Alzheimers Disease Assessment Scale – Cognitive Subscale (ADASCog)
Volume: 8 Issue: 3
Author(s): J. P. O'Halloran, A. S. Kemp, D. P. Salmon, P. N. Tariot and L. S. Schneider
Affiliation:
Keywords: CMINDS, cognitive assessment, computerized ADAS-Cog, concurrent validity, clinical trials, psychometric comparison, test-retest reliability, Alzheimer's Disease Assessment Scale, ideational praxis, mild cognitive impairment, ADCS, NINCDS, ADRDA, MMSE
Abstract: Background: The Alzheimers Disease Assessment Scale – Cognitive Subscale (ADAS-Cog) has become the de facto gold standard for assessing the efficacy of anti-dementia treatments. However, manual administration of the ADAS-Cog is subject to procedural inconsistencies, including scoring and transcription errors, which can introduce unwanted variance and compromise data quality within and across sites and trials. To address such concerns, a computerized version was developed that integrates, rather than replaces, the examiner, standardizes administration, and uses electronic data capture at the point of patient contact. The examiner can control administration and pacing, pause or repeat digitized instructions, score verbal report and overt behavioral performance, and freely interact with the subject. Purpose: To conduct psychometric comparisons of traditional, paper-based administration of the standard ADAS-Cog (sADAS) with examiner- assisted administration of the computerized ADAS-Cog (cADAS). Methods: Eighty-eight patients (39M; 49F) with mild to moderate Alzheimers disease were tested on three occasions with each version over a period of one year with one month between paired visits. Results: Intraclass Correlation Coefficients (ICC) comparisons between sADAS and cADAS were significant for total score (ICC=0.96) and all subscores (ICCs ranged 0.78-0.93), with no significant differences on paired t-tests. The mean ICCs across cADAS scores for test-retest reliability for short-term (mean ICC=0.96) and long-term (mean ICC=0.91) comparisons were significantly higher than across sADAS scores (mean ICCs were 0.87 and 0.84, respectively). Conclusions: These results indicate that examiner-assisted, computerized administration is equivalent to traditional, paper-based administration, and shows significantly greater test-retest reliability.
Export Options
About this article
Cite this article as:
P. O'Halloran J., S. Kemp A., P. Salmon D., N. Tariot P. and S. Schneider L., Psychometric Comparison of Standard and Computerized Administration of the Alzheimers Disease Assessment Scale – Cognitive Subscale (ADASCog), Current Alzheimer Research 2011; 8 (3) . https://dx.doi.org/10.2174/156720511795563692
DOI https://dx.doi.org/10.2174/156720511795563692 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nicotinamide and its Pharmacological Properties for Clinical Therapy
Drug Design Reviews - Online (Discontinued) Tolfenamic Acid Interrupts the De Novo Synthesis of the β-Amyloid Precursor Protein and Lowers Amyloid Beta Via a Transcriptional Pathway
Current Alzheimer Research Multiple Mechanisms of Cytokine Action in Neurodegenerative and Psychiatric States: Neurochemical and Molecular Substrates
Current Pharmaceutical Design Misoprostol Reverse Hippocampal Neuron Cyclooxygenase-2 Downstream Signaling Imbalance in Aluminum-Overload Rats
Current Alzheimer Research The Blood-Brain Barrier in NeuroAIDS
Current HIV Research East Meets West in the Search for Alzheimers Therapeutics - Novel Dimeric Inhibitors from Tacrine and Huperzine A
Current Alzheimer Research The Molecular Mechanism of <i>Scutellaria baicalensis</i> Georgi Stems and Leaves Flavonoids in Promoting Neurogenesis and Improving Memory Impairment by the PI3K-AKT-CREB Signaling Pathway in Rats
Combinatorial Chemistry & High Throughput Screening ATP-Binding Cassette Transporters in Inflammatory Brain Disease
Current Pharmaceutical Design Chronic Migraineurs Form Carboxyhemefibrinogen and Iron-Bound Fibrinogen
CNS & Neurological Disorders - Drug Targets Medicinal Chemistry of Antimigraine Drugs
Current Medicinal Chemistry Clinical Applications of Transcranial Doppler Sonography
Reviews on Recent Clinical Trials Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry Current Status of Anti-HIV Agents
Current Medicinal Chemistry - Anti-Infective Agents Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets Cognitive Changes Preceding Clinical Symptom Onset of Mild Cognitive Impairment and Relationship to ApoE Genotype
Current Alzheimer Research Study of the Effects of L-tryptophane Nanoparticles on Motor Behavior in Alzheimer's Experimental Models
CNS & Neurological Disorders - Drug Targets From Nature to Market: Examples of Natural Products that Became Drugs
Recent Patents on Biotechnology Statins and Carotid Intima-Media Thickness Reduction: An Up-to-Date Review
Current Medicinal Chemistry The Action of Polyphenols in Diabetes Mellitus and Alzheimer's Disease: A Common Agent for Overlapping Pathologies
Current Neuropharmacology Hippocampal Mean Diffusivity for the Diagnosis of Dementia and Mild Cognitive Impairment in Primary Care
Current Alzheimer Research